Ardelyx reiterates 2026 guidance as IBSRELA targets $1B in 2029 while advancing ACCEL CIC Phase III enrollment by year-end

Earnings Call Insights: Ardelyx (ARDX) Q1 2026

MANAGEMENT VIEW

*
“2026 is poised to be another significant year of growth for our company, and we're already off to a great start,” said (President, CEO & Director Michael Raab), adding that the company’s priorities are “accelerating the growth of IBSRELA, maintaining the XPHOZAH momentum, building and expanding our pipeline and delivering strong financial results.”

*
On IBSRELA, (CEO Michael Raab) said: “In the first quarter, our disciplined commercial execution drove 58% year-over-year revenue growth… and we remain on track to deliver at least $1 billion in annual revenue in 2029.”

*
On pipeline expansion, (CEO Michael Raab) said: “Earlier this year, we initiated the ACCEL trial, a Phase III clinical trial evaluating IBSRELA for chronic idiopathic constipation… We remain on track to complete enrollment by year-end and to announce top line data in the second half of 2027.”

*
Management also highlighted IP and leadership updates, with (CEO Michael Raab) citing “our recently announced Orange Book listed 2099 patent covering the commercial formulations of IBSRELA and XPHOZAH,” and stating: “I'm excited with the 2 newest additions who've joined the executive team, Felecia Ettenberg, our Chief Legal Officer; and Dr. Rajani Dinavahi, our Chief Medical Officer.”

*
From the CFO on financial positioning and capital allocation, (Chief Financial Officer Sue Hohenleitner) said: “We are driving towards profitability and meaningful cash generation,” and added: “Importantly, we are funding current operations and pipeline from our revenue base, which demonstrates the growing financial maturity of Ardelyx.”

OUTLOOK

*
(Chief Financial Officer Sue Hohenleitner) reiterated 2026 revenue guidance for IBSRELA and said: “We are reiterating our 2026 revenue guidance for IBSRELA between $410 million and $430 million.”

*
For XPHOZAH, (CFO Hohenleitner) said: “We are reiterating our revenue guidance between $110 million and $120 million in 2026.”

*
On the broader 2026 model, (CFO Hohenleitner) said: “Our full year product revenues are expected to grow between 38% and 46%, outpacing our operational expenses, which will grow by approximately 25%, consistent with prior guidance.”

*
Compared with the prior quarter’s call, management again emphasized Q1 seasonality and did not introduce a new framework for quarterly guidance, with (CEO Michael Raab) stating: “we're not going to get into the practice of quarter guidance.”

FINANCIAL RESULTS

*
(Chief Financial Officer Sue Hohenleitner) reported: “Our quarter-over-quarter total product revenues were $93.4 million compared to $67.8 million in the same period last year, representing 38% growth,” including “Q1 2026 revenues of $70.1 million” for IBSRELA and “$23.3 million” for XPHOZAH.

*
On XPHOZAH comparability, (CFO Hohenleitner) said: “in Q1 2025, we recorded a $3.8 million favorable adjustment related to product returns. Taking that adjustment into account, our paid prescriptions of XPHOZAH revenue actually grew 19% year-over-year.”

*
(CFO Hohenleitner) detailed spending levels tied to growth and ACCEL, reporting R&D expense of “$20.2 million” and SG&A expense of “$102.3 million” for Q1 2026.

*
Profitability metrics and liquidity were framed as improving but still loss-making, with (CFO Hohenleitner) reporting: “Our net loss for the first quarter of 2026 was $37.6 million or a loss of $0.15 per share,” and cash of “$238.1 million in total cash, cash equivalents and short-term investments.”

*
On financing, (CFO Hohenleitner) said: “we recently refinanced our existing debt with SLR,” adding it “extended the maturity and interest-only period… by 2 years and lowered our overall cost of capital,” while noting “The remaining $100 million of cash is available for drawdown this year.”

Q&A

*
Roanna Clarissa Ruiz, Leerink Partners: asked how Q1 demand resilience flows into the year; Chief Commercial Officer Foster answered: “We expect to continue to see quarter-over-quarter growth as we move forward,” while (CEO Raab) said the Q1 performance “only strengthens our conviction.”

*
Roanna Clarissa Ruiz, Leerink Partners: asked about 2026 OpEx cadence with ACCEL ramping; (CFO Hohenleitner) said: “we've said before… we're up to about $520 million in total OpEx… consistent throughout the quarters,” and (CEO Raab) added: “to be clear, that was all factored into the guidance.”

*
Jin-Wook Kim, Citi: asked whether CIC enrollment pace is tracking; (CEO Raab) said site start-up “was wonderful to see” and “enrollment continues at pace,” adding: “we're very confident with the time frame that we have shared.”

*
Yuchen Ding, Jefferies: pressed on Q1 seasonality, Q2 trajectory, and specialty pharmacy mix; (CEO Raab) responded: “it's not a recovery rather just the pattern of the business,” and (CCO Foster) said fulfillment is “absolutely” higher through the IBSRELA Pharmacy Network, with “an additional on average prescription… or refill” per year.

*
Yuchen Ding, Jefferies: asked about Lilly’s IBS-C program and durability; (CEO Raab) said: “I don't see that as a massive threat on the horizon.”

*
Christopher Raymond, Raymond James: asked about off-label CIC use and competitive dynamics; (CEO Raab) said: “physicians… can prescribe things off label. We cannot promote things off label,” and pointed to “Rome V” and the “continuum of care” as rationale for ACCEL.

*
Ashley Aloupis, Piper Sandler: asked about pediatric studies/patent extension and 531 timing; (CEO Raab) said: “We will work at pace if those studies are positive… we follow the data,” and called the 6-month pediatric exclusivity impact “significant.”

*
Joseph Thome, TD Cowen: asked about CIC call-point expansion and willingness to lever the balance sheet; (CCO Foster) said CIC could mean “more utilization in the primary care market,” while (CFO Hohenleitner) cited optionality from the refinance and said: “We still have access to an extra $100 million of that loan.”

*
Laura Chico, Wedbush: asked about field reimbursement manager impact and ACCEL quality/discontinuations; (CCO Foster) said the reimbursement team affects “both” breadth and depth by ensuring prescriptions “will be filled,” while (CEO Raab) emphasized clinical quality controls and noted screen failures “begin to taper.”

*
Prakhar Agrawal, Cantor Fitzgerald: asked about long-term XPHOZAH and GTN/cash flow; (CFO Hohenleitner) said: “we will reiterate the $750 million,” disclosed GTN “a little over 36.4%… a blend,” and said there is “a possibility we'll get to cash flow positivity.”

*
Matthew Caufield, H.C. Wainwright: asked for NRx/refill granularity; (CEO Raab) declined specifics and said: “we're seeing both… breadth and depth.”

SENTIMENT ANALYSIS

*
Analysts were slightly skeptical, repeatedly testing durability of IBSRELA growth through seasonality, channel strategy, competitive threats, and cash flow timing (e.g., Jefferies questioned “the recovery” and Cantor asked whether long-term targets were being reiterated).

*
Management tone was slightly positive in prepared remarks and more firm in Q&A when narrowing topics, with (CEO Michael Raab) stating: “we're not going to get into the practice of quarter guidance,” and reiterating ACCEL spend was “factored into the guidance.”

*
Versus the prior quarter, management continued a confident posture around long-term targets, but Q1 included more discussion of weather disruption and explicit refusal to provide quarterly cadence, alongside added detail on refinancing and capital allocation priorities.

QUARTER-OVER-QUARTER COMPARISON

*
Leadership and organizational updates were more prominent in Q1, including the introduction of a new Head of IR and two executive additions, while Q4 featured prepared pipeline detail from (Chief Patient Officer & Interim Chief Medical Officer Laura Williams) and Q1 shifted clinical leadership emphasis to the newly named CMO.

*
Guidance ranges for 2026 for both products were reiterated in Q1, consistent with Q4, while Q1 added explicit commentary on debt refinancing outcomes and reiterated that quarter-level guidance would not be provided.

*
Analyst focus was consistent across calls—IBSRELA demand drivers, pull-through/specialty pharmacy, CIC trial execution, and cash flow—while Q1 questions leaned more into near-term demand normalization after “storms and seasonality.”

RISKS AND CONCERNS

*
Weather and seasonal access dynamics were cited as demand risks, with (CCO Eric Foster) noting “expected first quarter market dynamics and temporary disruption from 2 severe winter storms,” and (CFO Sue Hohenleitner) emphasizing Q1 volatility as the reason they provided limited Q1 phasing color.

*
Competitive and market-structure uncertainty remained a topic, including potential future IBS-C entrants (Jefferies), and continued complexity in dialysis/phosphate management markets, which (CEO Michael Raab) described as “an opaque and difficult business.”

*
Execution risk around pipeline expansion was implicitly addressed through ACCEL operational updates, with (CEO Raab) pointing to all sites initiated “in under 4 months” and saying enrollment is “at pace.”

FINAL TAKEAWAY

Management described Q1 as reinforcing confidence in IBSRELA’s demand trajectory and reiterated full-year 2026 revenue guidance for both IBSRELA and XPHOZAH, while highlighting ACCEL’s rapid site initiation and a year-end enrollment goal with top-line data targeted for the second half of 2027. Executives also emphasized improving pull-through via the IBSRELA Pharmacy Network, maintained long-term targets including “at least $1 billion” for IBSRELA in 2029 and reiterated $750 million for XPHOZAH, and pointed to a debt refinancing that extended maturity and reduced cost of capital as part of preserving flexibility for pipeline investment and potential external opportunities.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/ardx/earnings/transcripts]

MORE ON ARDELYX

* Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4897169-ardelyx-inc-ardx-q1-2026-earnings-call-transcript]
* Why Ardelyx's Offensive Strategy Doesn't Move The Needle [https://seekingalpha.com/article/4873169-ardelyx-offensive-strategy-does-not-move-needle]
* Ardelyx, Inc. 2025 Q4 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4873018-ardelyx-inc-2025-q4-results-earnings-call-presentation]
* Ardelyx Q1 2026 Earnings Preview [https://seekingalpha.com/news/4581728-ardelyx-q1-2026-earnings-preview]
* Ardelyx gains after insider purchase, LPGA marketing deal [https://seekingalpha.com/news/4555790-ardelyx-stock-gains-marketing-deal-with-lpga]